EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Driving CAR therapies beyond T cells

Cecilie Ø Madsen, Thomas M Hulen, Maria Ormhøj, Sine R Hadrup, Inge M Svane, Özcan Met

Trends in Cancer · 2026

DOI: 10.1016/j.trecan.2026.02.008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026. Verfasst von Cecilie Ø Madsen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: Herlev Hospital, Beckett Foundation, Kirsten and Freddy Johansens Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T cell therapy has reshaped cancer immunotherapy for hematological malignancies, yet progress in solid tumors remains limited. Physical barriers, antigen heterogeneity, and immunosuppressive tumor microenvironment restrict the activity and persistence of CAR-T cells, while safety concerns complicate target selection. Extending CAR technology to alternative immune lineages, such as macrophages, natural killer cells, tumor-infiltrating lymphocytes, and unconventional T cells, offers complementary mechanisms for tumor recognition, infiltration, and immune modulation. This review highlights recent advances in these emerging CAR platforms, compares their biological and translational features, and outlines how integrating cell-intrinsic properties with CAR design may guide the next generation of cellular immunotherapies for solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenNeoplasmsHumansT-LymphocytesTumor MicroenvironmentLymphocytes, Tumor-InfiltratingKiller Cells, NaturalAnimalsReceptors, Antigen, T-CellMacrophages

Stichwörter der Autor:innen

CAR-T therapyNK cellsmacrophagestumor-infiltrating lymphocytesunconventional T cells

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • SDU Biotechnology, Department of Green Technology, University of Southern Denmark, Odense, Denmark.
  • Section for Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; Section for Experimental and Translational Immunology, Department of Health Technology, Techn…

Förderung

  • Herlev Hospital
  • Beckett Foundation
  • Kirsten and Freddy Johansens Foundation
  • Child Cancer Foundation

Zitieren

APA

Madsen, C. Ø., Hulen, T. M., Ormhøj, M., Hadrup, S. R., Svane, I. M., & Met, Ö. (2026). Driving CAR therapies beyond T cells. Trends in Cancer. https://doi.org/10.1016/j.trecan.2026.02.008

Vancouver

Madsen CØ, Hulen TM, Ormhøj M, Hadrup SR, Svane IM, Met Ö. Driving CAR therapies beyond T cells. Trends in Cancer. 2026. doi:10.1016/j.trecan.2026.02.008

BibTeX
@article{Madsen2026,
  author = {Madsen, Cecilie Ø and Hulen, Thomas M and Ormhøj, Maria and Hadrup, Sine R and Svane, Inge M and Met, Özcan},
  title = {Driving CAR therapies beyond T cells},
  journal = {Trends in Cancer},
  year = {2026},
  doi = {10.1016/j.trecan.2026.02.008}
}
Kostenlos starten →